MedTrace Logo

Detection of Breast Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC

NCT03480659 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 165

Last updated 2023-12-21

No results posted yet for this study

Summary

A central challenge in the fight against breast cancer is how to detect disease in a noninvasive manner before it is detectable by imaging methods. Although inroads have been made with more sensitive imaging techniques for earlier detection of breast cancer, these techniques are limited by the size of lesion that could be detected. Alternatively, several blood proteomic biomarkers have been proposed but none offer as of yet sufficient predictive power. Consequently, effective non-invasive tools as prognostic indicators and biomarkers of breast cancer are urgently needed.

The purpose of this study is to develop and test non-invasive biomarkers based on methylation changes in PBMC and circulated tumor DNA in breast cancer patients.

Conditions

Sponsors & Collaborators

  • Kazakh Research Institute of Oncology & Radiology

    collaborator OTHER

  • Montreal EpiTerapia Inc.

    collaborator INDUSTRY

  • Canada-Kazakhstan EpiTerapia Inc.

    collaborator INDUSTRY

  • HKGepitherapeutics

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-06-01
Primary Completion
2021-08-01
Completion
2021-09-01

Countries

  • Kazakhstan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03480659 on ClinicalTrials.gov